Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
PVLA
Stock Latest News
The Fly
Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
8d ago
PVLA
Premium
The Fly
Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program
15d ago
PVLA
Premium
Ratings
Buy Rating Reiterated on Palvella as QTORIN Data Strengthen and $227 Price Target Remains Unchanged
20d ago
PVLA
Premium
Ratings
Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path
21d ago
PVLA
Premium
Company Announcements
Palvella Reports Positive Phase 3 Data for QTORIN
22d ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics announces new data from SELVA, TOIVA studies
22d ago
PVLA
Premium
Company Announcements
Palvella Unveils Promising Phase 2 Data for QTORIN
27d ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics announces new data from TOIVA trial of Qtorin
27d ago
PVLA
Premium
Company Announcements
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market
29d ago
8K
PVLA
Premium
Ratings
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
1M ago
PVLA
Premium
The Fly
Palvella Therapeutics initiated with an Overweight at Stephens
1M ago
PVLA
Premium
The Fly
Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year
1M ago
PVLA
Premium
Company Announcements
Palvella Highlights QTORIN Progress and Financing in Q1 Update
1M ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics doses first patients in LOTU trial
1M ago
PVLA
Premium
Company Announcements
Palvella Therapeutics Adds Independent Dermatology Expert to Board
2M ago
8K
PVLA
Premium
Company Announcements
Palvella Showcases QTORIN Platform Momentum and Commercial Readiness
2M ago
8K
PVLA
Premium
Market News
3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
2M ago
KOD
PVLA
Premium
Ratings
De-Risked SELVA Trial Success and Scalable QTORIN Platform Underpin Buy Rating on Palvella
2M ago
PVLA
Premium
Ratings
Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway
2M ago
PVLA
Premium
The Fly
Palvella Therapeutics price target raised to $240 from $210 at Chardan
2M ago
PVLA
Premium
The Fly
Palvella Therapeutics price target raised to $210 from $200 at Oppenheimer
2M ago
PVLA
Premium
Company Announcements
Palvella Highlights 2025 Results and SELVA Phase 3 Progress
2M ago
8K
PVLA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
